{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:34:12Z","timestamp":1787027652820,"version":"build-2736575974"},"reference-count":50,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Backgrounds: Photodynamic therapy (PDT) is an established treatment modality in central serous chorioretinopathy (CSCR). The goal of our study was to evaluate the morphological and functional effects of PDT in patients with long-lasting CSCR and determine the related predictive factors for improvement. Methods: This retrospective analysis included consecutive patients with chronic CSCR who consented to PDT. The material comprised 98 eyes of 81 patients (67 males and 14 females) with a disease duration longer than 6 months followed for 6 months post treatment. All patients underwent a basic ophthalmological examination including best corrected visual acuity (BCVA) testing and imaging, spectral-domain optical coherence tomography (SD-OCT), and fluorescein angiography. Patients without macular neovascularization (MNV) were subjected to half-dose PDT (3 mg\/m2) with standard fluence (50 J\/cm2), guided by indocyanine green angiography. Cases complicated by MNV were subjected to full-dose PDT. Results: A morphological response, defined as complete resolution of subretinal fluid, was achieved in 76.29% of cases, and an improvement in BCVA of at least one logMAR line was obtained in 77.53% of cases. The mean BCVA gain was 1.2 logMAR line. All SD-OCT measurements (central retinal thickness, macular volume, mean subfield thickness, subretinal fluid height, and subfoveal choroidal thickness) showed a significant reduction post PDT. A multivariate analysis proved better morphological outcome associations with a younger age and male gender and better visual gains achieved in patients without intraretinal abnormalities. Univariate testing also showed strong relationships between better baseline BCVA and greater functional and morphological improvements, between shorter disease duration and morphological gains, and between the absence of MNV or intraretinal abnormalities and morphological gains. PDT was highly effective in providing a resolution of pigment epithelial detachment (p = 0.0004). The observed effect was significantly dependent upon the lower baseline central retinal thickness (p = 0.0095). Patients with intraretinal abnormalities or MNV showed moderate improvements post PDT. Conclusions: PDT in long-lasting CSCR cases provides good morphological results but generally minor visual gains. Patients\u2019 expectations of significant increases in BCVA after prolonged disease with distinct alterations of the neurosensory retina should be managed.<\/jats:p>","DOI":"10.3390\/biomedicines13040944","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T08:11:39Z","timestamp":1744704699000},"page":"944","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Predictive Factors for Morphological and Functional Improvements in Long-Lasting Central Serous Chorioretinopathy Treated with Photodynamic Therapy"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2901-0248","authenticated-orcid":false,"given":"Maciej","family":"Gaw\u0119cki","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Pomeranian Hospitals, 84-200 Wejherowo, Poland"},{"name":"Dobry Wzrok Ophthalmological Center, 80-392 Gdansk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0055-1125","authenticated-orcid":false,"given":"Krzysztof","family":"Kici\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Pomeranian Hospitals, 84-200 Wejherowo, Poland"},{"name":"Dobry Wzrok Ophthalmological Center, 80-392 Gdansk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8914-1798","authenticated-orcid":false,"given":"Jan","family":"Kucharczuk","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, 10th Military Research Hospital and Polyclinic, 85-681 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Go\u0142\u0119biowska-Bogaj","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Pomeranian Hospitals, 84-200 Wejherowo, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3724-2391","authenticated-orcid":false,"given":"Andrzej","family":"Grzybowski","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Warmia and Mazury, Oczapowskiego 2, 10-719 Olsztyn, Poland"},{"name":"Institute for Research in Ophthalmology, Foundation for Ophthalmology Development, Mickiewicza 24, 61-836 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.preteyeres.2015.05.003","article-title":"Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis","volume":"48","author":"Daruich","year":"2015","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/bjophthalmol-2018-312431","article-title":"Patient characteristics and risk factors for central serous chorioretinopathy: An analysis of 811 patients","volume":"103","author":"Ersoz","year":"2019","journal-title":"Br. J. Ophthalmol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"100770","DOI":"10.1016\/j.preteyeres.2019.07.003","article-title":"Central serous chorioretinopathy: Towards an evidence-based treatment guideline","volume":"73","author":"Yzer","year":"2019","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1097\/IAE.0000000000001443","article-title":"Acute central serous chorioretinopathy: Factors Influencing Episode Duration","volume":"37","author":"Daruich","year":"2017","journal-title":"Retina"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Gaw\u0119cki, M., Jaszczuk-Maciejewska, A., Jurska-Ja\u015bko, A., Kneba, M., and Grzybowski, A. (2019). Impairment of visual acuity and retinal morphology following resolved chronic central serous chorioretinopathy. BMC Ophthalmol., 19.","DOI":"10.1186\/s12886-019-1171-5"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"7792291","DOI":"10.1155\/2022\/7792291","article-title":"Efficacy of Navigated Laser Photocoagulation for Chronic Central Serous Chorioretinopathy: A Retrospective Observational Study","volume":"2022","author":"Zhou","year":"2022","journal-title":"Dis. Markers"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0002-9394(83)90265-9","article-title":"Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy","volume":"95","author":"Robertson","year":"1983","journal-title":"Am. J. Ophthalmol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1055\/a-2338-3235","article-title":"Laser Treatment of Central Serous Chorioretinopathy\u2014An Update","volume":"241","author":"Gawecki","year":"2024","journal-title":"Klin. Monbl. Augenheilkd."},{"key":"ref_9","first-page":"CD011841","article-title":"Interventions for central serous chorioretinopathy: A network meta-analysis","volume":"2015","author":"Salehi","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.oret.2022.04.014","article-title":"Crossover to Half-Dose Photodynamic Therapy or Eplerenone in Chronic Central Serous Chorioretinopathy Patients","volume":"6","author":"Feenstra","year":"2022","journal-title":"Ophthalmol. Retin."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.oret.2018.09.003","article-title":"Mineralocorticoid Receptor Antagonists in Central Serous Chorioretinopathy: A Meta-Analysis of Randomized Controlled Trials","volume":"3","author":"Wang","year":"2019","journal-title":"Ophthalmol. Retin."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ajo.2020.04.007","article-title":"Crossover to Photodynamic Therapy or Micropulse Laser After Failure of Primary Treatment of Chronic Central Serous Chorioretinopathy: The REPLACE Trial","volume":"216","author":"Scholz","year":"2020","journal-title":"Am. J. Ophthalmol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ophtha.2024.09.003","article-title":"Therapies for Central Serous Chorioretinopathy: A Report by the American Academy of Ophthalmology","volume":"132","author":"Kim","year":"2025","journal-title":"Ophthalmology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/00006982-200304000-00016","article-title":"Photodynamic therapy in chronic central serous chorioretinopathy","volume":"23","author":"Parodi","year":"2003","journal-title":"Retina"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/00006982-200306000-00002","article-title":"Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: A pilot study","volume":"23","author":"Yannuzzi","year":"2003","journal-title":"Retina"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Iacono, P., Da Pozzo, S., Varano, M., and Parravano, M. (2020). Photodynamic therapy with verteporfin for chronic central serous chorioretinopathy: A review of data and efficacy. Pharmaceuticals, 13.","DOI":"10.3390\/ph13110349"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Nassisi, M., Lavia, C., Alovisi, C., Musso, L., and Eandi, C.M. (2017). Short-term choriocapillaris changes in patients with central serous chorioretinopathy after half-dose photodynamic therapy. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18112468"},{"key":"ref_18","first-page":"4542","article-title":"Effect of low-dose photodynamic therapy at the choriocapillaris level on optical coherence tomography angiography in patients with chronic central serous chorioretinopathy","volume":"60","author":"Reifeltshammer","year":"2019","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"ref_19","first-page":"11206721211027060","article-title":"Early vessel occlusion and recanalization after photodynamic therapy in central serous chorioretinopathy by OCT angiography","volume":"23","year":"2021","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40662-023-00349-y","article-title":"Central serous chorioretinopathy: Updates in the pathogenesis, diagnosis and therapeutic strategies","volume":"10","author":"Zhang","year":"2023","journal-title":"Eye Vis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"100865","DOI":"10.1016\/j.preteyeres.2020.100865","article-title":"Central serous chorioretinopathy: An update on risk factors, pathophysiology and imaging modalities","volume":"79","author":"Kaye","year":"2020","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/IAE.0b013e3182670fbe","article-title":"Photodynamic therapy for chronic central serous chorioretinopathy: A 4-year follow-up study","volume":"33","author":"Silva","year":"2013","journal-title":"Retina"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00417-011-1900-9","article-title":"Retinal thickness changes following photodynamic therapy in chronic central serous chorioretinopathy","volume":"250","author":"Copete","year":"2012","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ajo.2016.07.026","article-title":"A multicenter study on the long-term outcomes of half-dose photodynamic therapy in chronic central serous chorioretinopathy","volume":"170","author":"Lai","year":"2016","journal-title":"Am. J. Ophthalmol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.oret.2020.07.026","article-title":"Central Serous Chorioretinopathy International Group. Multimodal imaging-based central serous chorioretinopathy classification","volume":"4","author":"Chhablani","year":"2020","journal-title":"Ophthalmol. Retin."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s40123-023-00687-z","article-title":"Biometric risk factors for central serous chorioretinopathy","volume":"12","author":"Grzybowski","year":"2023","journal-title":"Ophthalmol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s40123-022-00625-5","article-title":"Ganglion cell loss in the course of central serous chorioretinopathy","volume":"12","author":"Grzybowski","year":"2023","journal-title":"Ophthalmol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/IAE.0000000000002092","article-title":"Correlations between changes in photoreceptor layer and other clinical characteristics in central serous chorioretinopathy","volume":"39","author":"Yu","year":"2019","journal-title":"Retina"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"102235","DOI":"10.1016\/j.pdpdt.2021.102235","article-title":"Long term outer retinal changes in central serous chorioretinopathy submitted to half-dose photodynamic therapy","volume":"34","author":"Penas","year":"2021","journal-title":"Photodiagn. Photodyn. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ajo.2009.01.018","article-title":"Outer nuclear layer thickness at the fovea determines visual outcomes in resolved central serous chorioretinopathy","volume":"148","author":"Matsumoto","year":"2009","journal-title":"Am. J. Ophthalmol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Kamimura, A., Miki, A., Kishi, M., Okuda, M., Hayashida-Hirano, M., Sakamoto, M., Matsumiya, W., Imai, H., Kusuhara, S., and Nakamura, M. (2023). Two-year outcome of half-time photodynamic therapy for chronic central serous chorioretinopathy with and without choroidal neovascularization. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0284979"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Maruyama-Inoue, M., Yanagi, Y., Inoue, T., Kitajima, Y., and Kadonosono, K. (2024). Importance of fluorescein angiography as a predictor of treatment response in patients with pachychoroid neovasculopathy. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-79179-4"},{"key":"ref_33","first-page":"1356","article-title":"Single-session bilateral reduced-settings photodynamic therapy for bilateral chronic central serous chorioretinopathy","volume":"43","author":"Pauleikhoff","year":"2023","journal-title":"Retina"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1038\/s41433-022-02370-2","article-title":"Real world outcomes of photodynamic therapy for chronic central serous chorioretinopathy","volume":"37","author":"Khandhadia","year":"2023","journal-title":"Eye"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"100152","DOI":"10.1016\/j.xops.2022.100152","article-title":"Effectiveness of reduced-fluence photodynamic therapy for chronic central serous chorioretinopathy: A propensity score analysis","volume":"2","author":"Aisu","year":"2022","journal-title":"Ophthalmol. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/IAE.0000000000003686","article-title":"Increasing evidence for the safety of fovea-involving half-dose photodynamic therapy for chronic central serous chorioretinopathy","volume":"43","author":"Feenstra","year":"2023","journal-title":"Retina"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3928\/23258160-20191119-03","article-title":"Long-term efficacy and safety of photodynamic therapy in patients with chronic central serous chorioretinopathy","volume":"50","author":"Park","year":"2019","journal-title":"Ophthalmic Surg. Lasers Imaging Retin."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Wakatsuki, Y., Tanaka, K., Mori, R., Furuya, K., Kawamura, A., and Nakashizuka, H. (2021). Morphological changes and prognostic factors before and after photodynamic therapy for central serous chorioretinopathy. Pharmaceuticals, 14.","DOI":"10.3390\/ph14010053"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1007\/s00417-021-05531-3","article-title":"Risk factors of persistent subretinal fluid after half-dose photodynamic therapy for treatment-na\u00efve central serous chorioretinopathy","volume":"260","author":"Li","year":"2022","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00417-018-4003-z","article-title":"Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy","volume":"256","author":"Dijkman","year":"2018","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s40123-021-00336-3","article-title":"Structural OCT parameters associated with treatment response and macular neovascularization onset in central serous chorioretinopathy","volume":"10","author":"Arrigo","year":"2021","journal-title":"Ophthalmol. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1097\/IAE.0000000000003604","article-title":"Effects of half-dose photodynamic therapy on chronic central serous chorioretinopathy with or without macular neovascularization assessed using optical coherence tomography angiography","volume":"42","author":"Nakamura","year":"2022","journal-title":"Retina"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"104224","DOI":"10.1016\/j.pdpdt.2024.104224","article-title":"Clinical predictive factors and imaging biomarkers of treatment response to half dose PDT in patients with chronic central serous chorioretinopathy","volume":"48","author":"Mirshahi","year":"2024","journal-title":"Photodiagn. Photodyn. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"5859063","DOI":"10.1155\/2019\/5859063","article-title":"Outer nuclear layer as the main predictor to anatomic response to half dose photodynamic therapy in chronic central serous retinopathy","volume":"2019","author":"Sousa","year":"2019","journal-title":"J. Ophthalmol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1136\/bjo-2023-324147","article-title":"Foveal atrophy in patients with active central serous chorioretinopathy at first presentation: Characteristics and treatment outcomes","volume":"109","author":"Son","year":"2024","journal-title":"Br. J. Ophthalmol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1038\/s41433-021-01762-0","article-title":"Threshold thickness of foveal outer nuclear layer associated with outcomes of photodynamic therapy in central serous chorioretinopathy","volume":"36","author":"Yu","year":"2022","journal-title":"Eye"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Jeong, S., Kang, W., and Sagong, M. (2024). Influence of vortex vein engorgement for photodynamic therapy in central serous chorioretinopathy. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-75506-x"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40942-017-0073-z","article-title":"The comparison of multimodal imaging findings of central serous chorioretinopathy patients in regard to the early anatomically treatment response to half-fluence photodynamic therapy: A retrospective case-control study","volume":"3","author":"Ozkaya","year":"2017","journal-title":"Int. J. Retin. Vitr."},{"key":"ref_49","first-page":"e165","article-title":"Influence of scleral thickness on photodynamic therapy outcomes in central serous chorioretinopathy","volume":"103","author":"Forte","year":"2024","journal-title":"Acta Ophthalmol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.ophtha.2013.11.040","article-title":"Macula Society CSC Collaborative Study Group, Research and Education Committee and Website Committee. Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy","volume":"121","author":"Lim","year":"2014","journal-title":"Ophthalmology"}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/4\/944\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:13:13Z","timestamp":1760029993000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/4\/944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":50,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["biomedicines13040944"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines13040944","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]}}}